Skip to main content

SPRUCE BIOSCIENCES INC

For the period ended Dec 31, 2023. Filed Mar 18, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 18, 2024

SPRB$46.67-5.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (see signature pages)

POWER OFATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Javier Szwarcberg, M.D., MPH and Samir Gharib and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10‑K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Javier Szwarcberg, M.D., MPHChief Executive Officer and DirectorMarch 18, 2024
Javier Szwarcberg, M.D., MPH(Principal Executive Officer)
/s/ Samir GharibPresident and Chief Financial OfficerMarch 18, 2024
Samir Gharib(Principal Financial and Accounting Officer)
/s/ Michael GreyExecutive ChairmanMarch 18, 2024
Michael Grey
/s/ Tiba Aynechi, Ph.D.DirectorMarch 18, 2024
Tiba Aynechi, Ph.D.
/s/ Percival Barretto-KoDirectorMarch 18, 2024
Percival Barretto-Ko
/s/ Bali Muralidhar, M.D, Ph.D.DirectorMarch 18, 2024
Bali Muralidhar, M.D, Ph.D.
/s/ Niall O’Donnell, Ph.D.DirectorMarch 18, 2024
Niall O’Donnell, Ph.D.
/s/ Camilla V. Simpson, M.Sc.DirectorMarch 18, 2024
Camilla V. Simpson, M.Sc.
/s/ Daniel SpiegelmanDirectorMarch 18, 2024
Daniel Spiegelman
/s/ Kirk Ways, M.D, Ph.D.DirectorMarch 18, 2024
Kirk Ways, M.D, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.